Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Fulcrum Therapeutics auf Goldman Sachs Konferenz: Strategische Updates und Zukunftspläne | 3 | Investing.com Deutsch | ||
06.06. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 88 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
FULCRUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
29.05. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings | 1 | GlobeNewswire (USA) | ||
24.05. | Leerink raises Fulcrum Therapeutics stock to Outperform | 3 | Investing.com | ||
09.05. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 151 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
01.05. | Fulcrum Therapeutics GAAP EPS of -$0.28 beats by $0.01 | 3 | Seeking Alpha | ||
01.05. | Fulcrum Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
01.05. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | Uncovering Potential: Fulcrum Therapeutics' Earnings Preview | 2 | Benzinga.com | ||
22.04. | Pre-market Movers: Gelteq, MicroCloud Hologram, SHF Holdings, Orchestra Biomed, Fulcrum Therapeutics | 790 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.25 A.M. ET).In the Green Gelteq Ltd (GELS) is up over 445% at $5.05.
MicroCloud... ► Artikel lesen | |
11.04. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 144 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
05.03. | Fulcrum Therapeutics, MyoKardia end agreement on cardiomyopathy treatments | 1 | Seeking Alpha | ||
04.03. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
25.02. | Fulcrum Therapeutics GAAP EPS of -$0.31 misses by $0.03 | 3 | Seeking Alpha | ||
25.02. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 | 763 | GlobeNewswire (Europe) | ? On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ? ? Ended 2024 with... ► Artikel lesen | |
25.02. | Fulcrum Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
25.02. | Fulcrum Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
25.02. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
24.02. | Fulcrum Therapeutics Q4 2024 Earnings Preview | 2 | Seeking Alpha | ||
07.02. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 154 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 4,772 | -1,12 % | mRNA-Monsterdeal!: BioNTech schluckt CureVac - Aktie explodiert um über 30 Prozent! | © Foto: picture alliance/dpa | Sebastian GollnowBioNTech übernimmt CureVac für 1,25 Milliarden US-Dollar - aus Rivalen wird ein Team im Kampf gegen Krebs. Der Impfstoff-Pionier will mit dem Deal auch... ► Artikel lesen | |
QIAGEN | 40,680 | -0,01 % | Qiagen NV-Aktie gewinnt 1,15 Prozent (40,805 €) | Im Wertpapierhandel liegt die Aktie von Qiagen NV gegenwärtig im Plus. Das Wertpapier kostete zuletzt 40,81 Euro. Für die Aktie von Qiagen NV steht gegenwärtig ein Wertanstieg 1,15 Prozent zu Buche.... ► Artikel lesen | |
MODERNA | 23,180 | -1,19 % | Moderna-Aktie mit Kursgewinnen (25,1899 €) | Im Plus liegt zur Stunde die Aktie von Moderna . Das Papier notiert derzeit bei 28,72 US-Dollar. Ein Wertanstieg von 4,57 Prozent steht gegenwärtig für der Anteilsschein von Moderna zu Buche. Die Aktie... ► Artikel lesen | |
VALNEVA | 2,602 | -0,91 % | Valneva Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
AMGEN | 256,00 | +0,16 % | How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks? | ||
NOVAVAX | 5,969 | -0,58 % | Novavax: CIC And Flu Vaccine Candidates Induce Immune Responses Similar To Licensed Comparators | WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) reported results of the initial cohort of COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase... ► Artikel lesen | |
STRYKER | 328,50 | +0,55 % | Stryker receives FDA clearance for OptaBlate BVN Basivertebral Nerve Ablation System | Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/... ► Artikel lesen | |
BIOGEN | 112,50 | -0,57 % | UCB & Biogen: Phase 3 Trial Of Dapirolizumab Pegol In Systemic Lupus Erythematosus Meets Main Goal | WESTON (dpa-AFX) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L... ► Artikel lesen | |
ILLUMINA | 75,71 | +0,54 % | Zukunftsmarkt - hier geht es um 50 Mrd. USD: Illumina, Moderna, PanGenomic Health | Medizin wird persönlich. Die Zeit, in der Medikamente allen helfen sollen, naht ihrem Ende. Die Experten von BCC Research gehen davon aus, dass der Markt für personalisierte Medizin zwischen 2023 und... ► Artikel lesen | |
CRISPR THERAPEUTICS | 37,000 | +3,35 % | CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? | ||
REGENERON PHARMACEUTICALS | 460,70 | +0,55 % | Regeneron Pharmaceuticals-Aktie heute stark gefragt: Kurs legt deutlich zu (450,0718 €) | Grund zur Freude haben Aktionäre von Regeneron Pharmaceuticals : Der Kurs der Aktie legt kräftig zu. Zu den Performancebesten an der Börse zählt zur Stunde die Aktie von Regeneron Pharmaceuticals. Im... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,418 | -0,41 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
VIKING THERAPEUTICS | 23,030 | +2,02 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
EDITAS MEDICINE | 1,692 | -0,56 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
IDEXX LABORATORIES | 452,90 | +0,09 % | IDEXX Laboratories Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) |